Literature DB >> 17073776

Biodiversity of CYP51 in trypanosomes.

G I Lepesheva1, T Y Hargrove, R D Ott, W D Nes, M R Waterman.   

Abstract

Sterol 14alpha-demethylases (CYP51) are metabolic cytochromes P450, found in each biological kingdom. They catalyse a single three-step reaction included in all sterol biosynthetic pathways. Plant CYP51s have strict preference towards their physiological substrate O (obtusifoliol), which is C-4-monomethylated. Natural substrates of animal/fungal CYP51 (lanosterol, 24,25-dihydrolanosterol or 24-methylenelanosterol) are C-4-dimethylated. CYP51 from the pathogenic protozoa TB (Trypanosoma brucei) is the first example of O-specific sterol 14alpha-demethylase in non-photosynthetic organisms. Surprisingly, at 83% amino acid identity to the TB orthologue, CYP51 from TC (Trypanosoma cruzi) clearly prefers C-4-dimethylated sterols. Replacement of animal/fungi-like Ile(105) in the B' helix of TC CYP51 with phenylalanine, the residue found in this position in all plant and other trypanosome CYP51s, dramatically increases the ability of the enzyme to metabolize O, converting it into a more plant-like sterol 14alpha-demethylase. A more than 100-fold increase in binding and turnover is observed for the 24-desmethyl analogue of O [N (norlanosterol)], which is found in vivo in procyclic forms of TB and is a good TB CYP51 substrate in vitro. We believe that (i) N is a non-conventional CYP51 substrate, preferred in TB and perhaps other Trypanosomatidae and (ii) functional similarity of TC CYP51 to animal/fungal orthologues is a result of evolutionary convergence (including F105I mutation), leading to different pathways for sterol production in TC versus TB.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17073776     DOI: 10.1042/BST0341161

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  12 in total

1.  Substrate preferences and catalytic parameters determined by structural characteristics of sterol 14alpha-demethylase (CYP51) from Leishmania infantum.

Authors:  Tatiana Y Hargrove; Zdzislaw Wawrzak; Jialin Liu; W David Nes; Michael R Waterman; Galina I Lepesheva
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

Review 2.  Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51).

Authors:  Galina I Lepesheva; Fernando Villalta; Michael R Waterman
Journal:  Adv Parasitol       Date:  2011       Impact factor: 3.870

Review 3.  Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis.

Authors:  Galina I Lepesheva; Michael R Waterman
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

Review 4.  Structural basis for conservation in the CYP51 family.

Authors:  Galina I Lepesheva; Michael R Waterman
Journal:  Biochim Biophys Acta       Date:  2010-06-11

5.  Structural complex of sterol 14α-demethylase (CYP51) with 14α-methylenecyclopropyl-Delta7-24, 25-dihydrolanosterol.

Authors:  Tatiana Y Hargrove; Zdzislaw Wawrzak; Jialin Liu; Michael R Waterman; W David Nes; Galina I Lepesheva
Journal:  J Lipid Res       Date:  2011-11-30       Impact factor: 5.922

6.  Podophyllotoxin analogues active versus Trypanosoma brucei.

Authors:  Md Jashim Uddin; David C Smithson; Kristin M Brown; Brenda C Crews; Michele Connelly; Fangyi Zhu; Lawrence J Marnett; R Kiplin Guy
Journal:  Bioorg Med Chem Lett       Date:  2010-01-11       Impact factor: 2.823

7.  CYP51: A major drug target in the cytochrome P450 superfamily.

Authors:  Galina I Lepesheva; Tatyana Y Hargrove; Yuliya Kleshchenko; W David Nes; Fernando Villalta; Michael R Waterman
Journal:  Lipids       Date:  2008-09-04       Impact factor: 1.880

8.  Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth.

Authors:  Galina I Lepesheva; Robert D Ott; Tatiana Y Hargrove; Yuliya Y Kleshchenko; Inge Schuster; W David Nes; George C Hill; Fernando Villalta; Michael R Waterman
Journal:  Chem Biol       Date:  2007-11

9.  Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease.

Authors:  Jennifer Riley; Stephen Brand; Michael Voice; Ivan Caballero; David Calvo; Kevin D Read
Journal:  PLoS Negl Trop Dis       Date:  2015-09-22

10.  Triazole derivatives with improved in vitro antifungal activity over azole drugs.

Authors:  Shichong Yu; Xiaoyun Chai; Yanwei Wang; Yongbing Cao; Jun Zhang; Qiuye Wu; Dazhi Zhang; Yuanying Jiang; Tianhua Yan; Qingyan Sun
Journal:  Drug Des Devel Ther       Date:  2014-04-10       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.